• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Sep 2001; 60(9): 869–875.
PMCID: PMC1753835

Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial

Abstract

OBJECTIVE—To determine whether a patient education programme (PE) would improve rates of adherence to a slow acting antirheumatic drug and to assess any subsequent effect on patient outcome.
METHODS—A randomly controlled study comprising 100 patients with rheumatoid arthritis (49 control CG; 51 experimental EG) requiring D-penicillamine (DPA). The same practitioner saw patients on seven occasions, for the same length of time. The EG received 7 × 30 minute one to one sessions of PE, while the CG received standard management. The primary measure of adherence was a pharmacological marker (phenobarbitone) encapsulated with the DPA assayed at monthly intervals for six months. Plasma viscosity (PV), C reactive protein, articular index, morning stiffness, and pain score were used to assess outcome.
RESULTS—454 blood samples were collected and assayed and the pharmacological marker showed the EG to be significantly more adherent on more occasions than the CG (p<0.05). Patterns of adherence over time showed that at 12 weeks 86% (38/44) of those in the EG compared with 64% (29/45) of the CG remained adherent (p=0.01). These trends continued and by the end of the study 85% (29/34) of the EG compared with 55% (23/42) of the CG were taking their DPA as prescribed. Fifteen patients (12 from the EG) experienced side effects requiring study withdrawal and 14 patients requested study withdrawal (two from the EG). On study entry patients in the CG had significantly higher levels of PV than the EG and this remained so throughout the research. However, on completion, the health status of patients in both groups had improved significantly (p<0.01).
CONCLUSIONS—PE significantly increased adherence to DPA and its effects persisted over a period of six months. No additional clinical benefit was detected in the EG in comparison with the CG.

Full Text

The Full Text of this article is available as a PDF (161K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol. 1996 Aug;35(8):781–790. [PubMed]
  • van Gestel AM, Haagsma CJ, Furst DE, van Riel PL. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Baillieres Clin Rheumatol. 1997 Feb;11(1):65–82. [PubMed]
  • Belcon MC, Haynes RB, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum. 1984 Nov;27(11):1227–1233. [PubMed]
  • Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992 Mar;34(5):507–513. [PubMed]
  • Bradley LA. Adherence with treatment regimens among adult rheumatoid arthritis patients: current status and future directions. Arthritis Care Res. 1989 Sep;2(3):S33–S39. [PubMed]
  • Pullar T, Peaker S, Martin MF, Bird HA, Feely MP. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br J Rheumatol. 1988 Oct;27(5):381–384. [PubMed]
  • Doyle DV, Perrett D, Foster OJ, Ensor M, Scott DL. The long-term use of D-penicillamine for treating rheumatoid arthritis: is continuous therapy necessary? Br J Rheumatol. 1993 Jul;32(7):614–617. [PubMed]
  • Lorig K, Konkol L, Gonzalez V. Arthritis patient education: a review of the literature. Patient Educ Couns. 1987 Dec;10(3):207–252. [PubMed]
  • Hirano PC, Laurent DD, Lorig K. Arthritis patient education studies, 1987-1991: a review of the literature. Patient Educ Couns. 1994 Aug;24(1):9–54. [PubMed]
  • Hawley DJ. Psycho-educational interventions in the treatment of arthritis. Baillieres Clin Rheumatol. 1995 Nov;9(4):803–823. [PubMed]
  • Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977 Mar;84(2):191–215. [PubMed]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. [PubMed]
  • Pincus T. Formal educational level--a marker for the importance of behavioral variables in the pathogenesis, morbidity, and mortality of most diseases? J Rheumatol. 1988 Oct;15(10):1457–1460. [PubMed]
  • Hill J, Bird HA, Hopkins R, Lawton C, Wright V. The development and use of Patient Knowledge Questionnaire in rheumatoid arthritis. Br J Rheumatol. 1991 Feb;30(1):45–49. [PubMed]
  • Wolff K, Hay A, Raistrick D, Calvert R, Feely M. Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to "estimate" methadone plasma levels. Clin Pharmacol Ther. 1991 Aug;50(2):199–207. [PubMed]
  • Bignell CJ, Mulcahy FM, Peaker S, Pullar T, Feely MP. Measuring treatment compliance of men with non-gonococcal urethritis receiving oxytetracycline combined with low dose phenobarbitone. Genitourin Med. 1988 Oct;64(5):312–315. [PMC free article] [PubMed]
  • Peaker S, Mehta AC, Kumar S, Feely M. Measurement of low (sub-therapeutic) phenobarbitone levels in plasma by high-performance liquid chromatography: application to patient compliance studies. J Chromatogr. 1989 Dec 29;497:308–312. [PubMed]
  • Owen SG, Friesen WT, Roberts MS, Flux W. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol. 1985 Nov;24(4):313–320. [PubMed]
  • Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis. 1998 Mar;57(3):146–151. [PMC free article] [PubMed]
  • Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ. 1999 Sep 4;319(7210):612–615. [PMC free article] [PubMed]
  • Helliwell PS, O'Hara M, Holdsworth J, Hesselden A, King T, Evans P. A 12-month randomized controlled trial of patient education on radiographic changes and quality of life in early rheumatoid arthritis. Rheumatology (Oxford) 1999 Apr;38(4):303–308. [PubMed]
  • Dunbar J, Dunning EJ, Dwyer K. Compliance measurement with arthritis regimen. Arthritis Care Res. 1989 Sep;2(3):S8–16. [PubMed]
  • Pullar T. Compliance with drug therapy. Br J Clin Pharmacol. 1991 Nov;32(5):535–539. [PMC free article] [PubMed]
  • Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997 May;32(5):345–356. [PubMed]
  • Brooks PM, Miners JO, Smith K, Smith MD, Fearnley I, Birkett DJ. Dose, plasma concentration and response relationships of D-penicillamine in patients with rheumatoid arthritis. J Rheumatol. 1984 Dec;11(6):772–775. [PubMed]
  • Butler M, Carruthers G, Harth M, Freeman D, Percy J, Rabenstein D. Pharmacokinetics of reduced D-penicillamine in patients with rheumatoid arthritis. Arthritis Rheum. 1982 Jan;25(1):111–116. [PubMed]
  • Lorig K, Holman H. Arthritis self-management studies: a twelve-year review. Health Educ Q. 1993 Spring;20(1):17–28. [PubMed]
  • Barlow JH, Turner AP, Wright CC. Long-term outcomes of an arthritis self-management programme. Br J Rheumatol. 1998 Dec;37(12):1315–1319. [PubMed]
  • Lindroth Y, Bauman A, Brooks PM, Priestley D. A 5-year follow-up of a controlled trial of an arthritis education programme. Br J Rheumatol. 1995 Jul;34(7):647–652. [PubMed]
  • Taal E, Riemsma RP, Brus HL, Seydel ER, Rasker JJ, Wiegman O. Group education for patients with rheumatoid arthritis. Patient Educ Couns. 1993 May;20(2-3):177–187. [PubMed]

Figures and Tables

Figure 1
Levels of adherence over a six month period—analysis 1. *Difference significant at the 5% level.
Figure 2
Levels of adherence over a six month period—analysis 2. *Difference significant at the 5% level.

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...